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ABSTRACT
Introduction Scabies is a significant contributor to global 
morbidity, affecting approximately 200 million people at 
any time. Scabies is endemic in many resource- limited 
tropical settings. Bacterial skin infection (impetigo) 
frequently complicates scabies infestation in these 
settings. Community- wide ivermectin- based mass drug 
administration (MDA) is an effective control strategy for 
scabies in island settings, with a single round of MDA 
reducing population prevalence by around 90%. However, 
current two- dose regimens present a number of barriers 
to programmatic MDA implementation. We designed the 
Regimens of Ivermectin for Scabies Elimination (RISE) trial 
to investigate whether one- dose MDA may be as effective 
as two- dose MDA in controlling scabies in high- prevalence 
settings.
Methods and analysis RISE is a cluster- randomised 
non- inferiority trial. The study will be conducted in 20 
isolated villages in Western Province of Solomon Islands 
where population prevalence of scabies is approximately 
20%. Villages will be randomly allocated to receive either 
one dose or two doses of ivermectin- based MDA in a 1:1 
ratio. The primary objective of the study is to determine 
if ivermectin- based MDA with one dose is as effective as 
MDA with two doses in reducing the prevalence of scabies 
after 12 months. Secondary objectives include the effect 
of ivermectin- based MDA on impetigo prevalence after 12 
and 24 months, the prevalence of scabies at 24 months 
after the intervention, the impact on presentation to health 
facilities with scabies and impetigo, and the safety of one- 
dose and two- dose MDA.
Ethics and dissemination This trial has been approved 
by the ethics review committees of the Solomon Islands 
and the Royal Children's Hospital, Australia. Results will 
be disseminated in peer- reviewed publications and in 
meetings with the Solomon Islands Ministry of Health and 
Medical Services and participating communities.
Trial registration details Australian New Zealand Clinical 
Trials Registry: ACTRN12618001086257. Date registered: 
28 June 2018.
BACKGROUND
Scabies is a neglected tropical disease 
(NTD) caused by infestation with the mite 
Sarcoptes scabiei var. hominis. Scabies is a signif-
icant contributor to global morbidity, esti-
mated to cause 455 million annual incident 
cases.1 2 Transmission occurs primarily as 
a result of skin- to- skin contact (and rarely 
due to fomites) and is more common in 
overcrowded settings, including in many 
tropical environments where crowding and 
poverty are prevalent and access to treatment 
limited.3 4 The burden of disease is substan-
tial in many Pacific Island Countries where 
scabies affects one in five people and up to 
one in two children.5
Scabies infestation causes intense itch and 
discomfort. Furthermore, it is responsible 
for a considerable proportion of bacterial 
skin infection (impetigo) in many resource- 
limited settings.6–8 Scabies causes a breach 
Strengths and limitations of this study
 ► The cluster- randomised study design follows the 
implementation of the intervention at a village level
 ► Follow- up at both 12 and 24 months will demon-
strate longer term effects of the intervention
 ► The sample size (5000 people across 20 villages) 
achieves a statistical power of 80%
 ► This study is being conducted in partnership with 
the Solomon Islands Ministry of Health and Medical 
Service in a culturally sensitive manner and will 
build the capacity of local nursing staff
 ► Scabies prevalence is high in the isolated island 
villages where this study will be conducted (ap-
proximately 20%), therefore results may not be 
transferable to lower prevalence or urban settings
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in the skin barrier from scabetic lesions and subsequent 
scratching, creating an entry point for bacteria, including 
Staphylococcus aureus and Streptococcus pyogenes. Resulting 
impetigo can in turn cause severe infection and immune- 
mediated disease, including sepsis, glomerulonephritis 
and possibly rheumatic fever.9–12
Treatment guidelines for scabies recommend treat-
ment of the infected individual as well as household 
contacts.13 14 Most guidelines recommend treatment 
with topical acaracides such as permethrin or benzoyl 
benzoate.13 14 These medications are effective, if applied 
to all affected areas for the correct duration, but re- infes-
tation frequently occurs in highly endemic settings where 
individuals may be exposed to infected household or 
community members, many of whom may be asymptom-
atic.15 Therefore, attention has shifted to simultaneous 
treatment of whole communities, including those without 
symptoms of infestation, to reduce prevalence and the 
rate of transmission.16 This strategy of mass drug admin-
istration (MDA) has been used to successfully control a 
number of NTDs, including onchocerciasis, lymphatic 
filariasis (LF), trachoma and soil- transmitted helminths, 
and there is a growing body of evidence to support MDA 
for scabies control.17–22
Ivermectin is an antiparasitic drug in the avermectin 
class that is active against the scabies mite. Ivermectin- 
based MDA for scabies involves offering ivermectin treat-
ment to the whole community, with the exception of young 
children, pregnant women and others with a contraindi-
cation to ivermectin. Permethrin cream is offered as an 
alternative to ivermectin for these groups. Several studies 
in Pacific Island Countries with high- prevalence have 
shown ivermectin- based MDA can reduce the popula-
tion prevalence of scabies by around 90%.7 17 23 The Skin 
Health Intervention Fiji Trial (SHIFT) study in Fiji was 
the first comparative study to demonstrate the effective-
ness of ivermectin MDA for scabies control, finding a 
reduction in the population prevalence of scabies from 
32% at baseline to less than 2% at 12 months.21 These 
trials have all used an MDA strategy involving two doses of 
medication, given 7 to 14 days apart (either to the whole 
community or those with clinical signs of scabies).7 23 This 
is consistent with clinical recommendations for treatment 
of individuals.13 Ivermectin is known to lack ovicidal 
activity, therefore the second dose aims to kill newly 
hatched mites.24
In 2017, the WHO recognised scabies as a NTD, and 
identified the need for public health action to control 
scabies in endemic settings.9 The Strategic and Technical 
Advisory Group on Neglected Tropical Diseases called for 
further research into control strategies for scabies and 
the development of guidelines for the public health use 
of avermectins.25
While ivermectin- based MDA shows great promise as 
a control strategy for scabies, the requirement for two 
doses of medication at each MDA round presents barriers 
to implementation. Drug and implementation costs are 
doubled compared with single- dose MDA. Distribution 
is more complex and integration with programmes for 
other NTDs is difficult. These challenges are ampli-
fied in remote island settings where the population is 
dispersed across difficult to reach villages and funding for 
programmes is limited. These hurdles may be prohibitive 
to widespread implementation of scabies control, partic-
ularly in low- income settings. Therefore, the optimum 
dosing strategy for MDA remains an important knowl-
edge gap.9 For this reason, we designed the Regimens of 
Ivermectin for Scabies Elimination (RISE) trial.
METHODS AND ANALYSIS
Study design
The RISE trial is a prospective, open- label comparison of 
one dose versus two doses of ivermectin- based MDA for 
the population- level control of scabies (table 1). Using a 
cluster- randomised design, 20 villages will be randomised 
to one of two intervention groups in a 1:1 ratio. Randomi-
sation will occur at the village level, rather than the indi-
vidual level, as the objective is to determine the dosing 
regimen for controlling scabies within whole communi-
ties. Randomisation minimises the possibility of the antic-
ipated difference in the outcome between each group 
being confounded. A two- dose regimen is an appropriate 
comparator (rather than no- treatment or placebo) as two- 
doses of ivermectin- based MDA is the currently accepted 
dosing regimen. We chose a non- inferiority design 
because it is unlikely that a one- dose regimen would be 
superior in effectiveness to a two- dose regimen.
However, the logistic and pragmatic advantages of a 
one- dose regimen compared with a two- dose regimen 
make a non- inferior study appealing.
The prevalence of scabies and impetigo will be 
measured before the intervention (baseline), and 
repeated at 12 and 24 months after the intervention. To 
measure a secondary outcome, the standard Solomon 
Islands Ministry of Health and Medical Services (MHMS) 
health facility reporting processes will be used to capture 
the number of presentations to health facilities with 
scabies and impetigo in the study catchment area for 
the 12- month period before the intervention and for the 
24- month period after the intervention.
Aims
The primary objective of this study is to determine if 
ivermectin- based MDA with one dose is non- inferior 
to two doses in reducing the prevalence of scabies 12 
months after the intervention. The secondary objectives 
are to assess the impact of ivermectin- based MDA on: 
population prevalence of scabies after 24 months; popu-
lation prevalence of impetigo after 12 and 24 months; the 
number of presentations to health clinics with scabies and 
impetigo before and after the intervention; the number 
of adverse events measured by passive surveillance in 
the 12 months after MDA in each study group. The trial 
will also be measuring outcomes related to the impact 
of ivermectin MDA on the prevalence and intensity of 
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soil- transmitted helminths; however, this paper focusses 
on scabies and impetigo outcomes.
Rationale
This study uses ivermectin- based MDA because the 
SHIFT trial in Fiji demonstrated the greatest reduction 
in scabies prevalence after ivermectin- based MDA.21 
Ivermectin is currently the only oral therapy available 
for scabies and it allows greater compliance than with 
topical therapy. Oral therapy can be directly observed, 
ensuring adherence to treatment. Although ivermectin 
only kills the mature scabies mite and not the eggs, a 
single dose of treatment simultaneously administered 
to a whole village may reduce transmission sufficiently 
to reduce population prevalence. A recent Cochrane 
review did not find a difference in efficacy of one dose 
of oral ivermectin compared with two doses of oral 
ivermectin, but confidence in the effect estimates was 
low- to- moderate, with poor reporting being a major 
limitation.26 A retrospective study in Zanzibar of six 
rounds of annual single- dose ivermectin MDA for 
LF showed a 68% to 98% decline in clinical presenta-
tions and treatments for scabies, suggesting a one- dose 
strategy may significantly reduce transmission.27 By 
contrast, annual ivermectin MDA for LF did not reduce 
the prevalence of scabies in Tanzania where the baseline 
prevalence was less than 5%.28
Study setting and participants
The study will be conducted in Western Province of 
Solomon Islands (figures 1 and 2). Solomon Islands is 
a nation in the South Pacific with a population of over 
650 000 spread across 900 islands, a geography that 
presents many challenges for health service delivery.29 
Solomon Islands is classified as a least developed country. 
It is ranked 152 out of 189 on the Human Development 
Index.30 The majority of the population depend on subsis-
tence agriculture in rural locations. We chose Western 
Province for this study for several reasons: first, there is 
a high burden of scabies—a 2014 survey estimated an 
all- age scabies prevalence of 19.2%6; second, we expect 
that there will be relatively little mixing between villages 
because of the island geography of isolated villages with 
no road transport; third, there are many villages of appro-
priate population size (between 180 and 300) for the 
cluster- randomised design.
Twenty villages will be selected after close consultation 
with the MHMS. Criteria for selecting the villages include 
a population of between 180 and 300 people, geographic 
isolation and willingness to participate in the study. All 
residents of the 20 selected villages will be eligible to 
participate. If a resident of a two- dose village does not 
take the first dose of medication, they will still be eligible 
to take a dose when the team returns to the village for the 
second dose.
Table 1 Key features of the RISE trial
Primary objective To determine if ivermectin- based MDA with one dose is non- inferior to two- doses in reducing 
prevalence of scabies at 12 months
Secondary objectives Impact of one versus two dose ivermectin- based MDA on:
 ► Population prevalence of scabies at 24 months
 ► Population prevalence of impetigo at 12 and 24 months
 ► Number of presentations to health clinics with scabies and impetigo
 ► Number of adverse events measured by passive surveillance in the 12- month period following 
MDA
Design Prospective, open- label comparison using a cluster- randomised design
Sample size 20 villages (approximately 5000 participants), randomised in a 1:1 ratio to each intervention group
Intervention Group 1: one dose of ivermectin- based MDA
Group 2: two doses of ivermectin- based MDA given 7 to 14 days apart
Study setting Western Province, Solomon Islands (scabies prevalence approximately 20%)
Inclusion criteria All residents in the study villages
Exclusion criteria Participants who meet exclusion criteria will not receive treatment but will still be eligible to enrol in 
the study and undergo skin examination Exclusion criteria are: allergy to ivermectin or permethrin; 
treatment within the last 7 days with ivermectin or permethrin; participant declines treatment
If ivermectin is contraindicated, topical permethrin will be offered. Contraindications for ivermectin 
include: pregnancy; breastfeeding an infant less than 7 days old; age less than 2 years; height less 
than 90 cm; concurrent medication that may interact with ivermectin (for example, warfarin); or 
severe, acute or chronic illness on the day of MDA
Outcome measures Presence of scabies and impetigo measured by clinical examination
Conducted by trained nurses and assessed using the 2020 International Alliance for the Control of 
Scabies criteria
Assessments will be conducted at baseline, 12 and 24 months
MDA, mass drug administration; RISE, Regimens of Ivermectin for Scabies Elimination.
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This is a community- based study, with analysis 
conducted at the village level, and therefore, all residents 
are eligible to participate in the follow- up assessment at 
12 and 24 months, regardless of whether they received 
treatment at baseline. Written informed consent will be 
obtained from all participants. Participants under the age 
18 years will require written consent to be provided by 
a parent or guardian. Consent will be obtained at each 
study time point (baseline, 12 months and 24 months) 
(online supplementary file 1).
Inclusion and exclusion criteria
Inclusion criteria
All participants who provide consent are eligible to partic-
ipate. If exclusion criteria for treatment are met, then 
consented participants are still eligible to have their skin 
examined.
Exclusion criteria
Participants who meet any of the following criteria will 
not receive treatment, but will be eligible to enrol in 
Figure 1 Study location in Solomon Islands.
Figure 2 Study location in Western Province, Solomon Islands.
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the study and undergo skin examination: allergy to iver-
mectin or permethrin; treatment within the last 7 days 
with ivermectin or permethrin; or declines treatment.
If ivermectin is contraindicated, then topical perme-
thrin will be offered. The contraindications for iver-
mectin are: pregnancy; breastfeeding an infant less than 
7 days old; age less than 2 years; height less than 90 cm; 
concurrent medication that may interact with ivermectin 
(eg, warfarin); or severe acute or chronic illness on the 
day of MDA.
Patient and public involvement statement
The trial was designed in close consultation with stake-
holders at the Solomon Islands MHMS to ensure it was 
culturally appropriate for the local setting. Staff from the 
Solomon Islands MHMS contributed to study design and 
identification of study sites. The study team will comprise 
a majority of Solomon Islander staff from Western Prov-
ince. Staff are able to communicate in the local regional 
languages.
A team of health promotion officers from the Solomon 
Islands MHMS will conduct community awareness in each 
village, approximately 1 month prior to MDA. An illus-
trated information leaflet outlining the study design as 
well as information about scabies and the treatments will 
be provided during community visits. A participant infor-
mation statement that contains contact details for the 
principal investigator and local investigator will be made 
available to all village residents. Community awareness 
and the informed consent process will be conducted in 
Solomon Islands Pijin and study staff who speak the local 
regional language will be available to provide further 
information or clarification as required. Results of the 
study will be communicated to community leaders and 
members by the study team.
Intervention
Oral ivermectin will be offered to all participants, unless 
there is a contraindication to ivermectin. A dose of 
200 µg/kg of ivermectin is recommended for the treat-
ment of individuals with scabies.13 31 We will aim to dose 
ivermectin within a range of 150 to 250 µg/kg, as this dose 
has been effective in previous trials.21 We will use 6 mg 
scored tablets. Doses will be rounded to the nearest 3 mg. 
The tablets will be accurately halved on the score line 
using a pill cutter as required. As weight scales are gener-
ally unsuitable for implementation of MDA, we will use 
dosing strategies appropriate for larger scale program-
matic roll- out.
We will use height- based dosing for children aged less 
than 15 years, with doses ranging from 3 mg to 12 mg, 
as is standard for MDA for onchocerciasis and LF.32 33 
Adults will receive a standard dose of 12 mg, with doses 
adjusted based on visual assessment of body shape (9 mg 
for adults assessed to be malnourished and 15 mg for 
adults assessed to be obese). Drug distribution staff will 
make these assessments based on a series of body shape 
silhouettes.34 Dosing of medications for MDA based on 
physical appearance has been shown to be accurate and 
safe.33 Staff will undergo training and validation for these 
dosing techniques. Ivermectin will be administered by 
trained study staff who will directly observe swallowing of 
the tablets.
Topical permethrin 5% cream will be given to partic-
ipants meeting exclusion criteria for ivermectin. Perme-
thrin will be dosed according to clinical guidelines.35 
Participants or carers will be counselled to apply the 
cream to the whole body from the neck down (in infants 
cream should also be applied to the scalp) and to leave it 
for 8 to 14 hours, or 4 hours in infants less than 2 months 
of age.
Outcome measures
All participants will undergo assessment for symptoms 
and signs of scabies, impetigo and other skin disease.36 
Assessment will include history questions regarding 
the presence of itch, contact history and a simplified 
skin examination. Skin examination will be limited to 
areas that are usually exposed (arms from above elbow 
to fingers, legs from above knee to toes, and head and 
neck). Other areas (including breasts, groin or genitals) 
will not be examined. Data suggest that, in this setting, 
a limited examination detects more than 90% cases of 
scabies.36 The skin of children less than 2 years age will be 
examined more generally, as scabies may be more wide-
spread in this age group.3
Scabies will be diagnosed according to consensus 
criteria established by the International Alliance for 
the Control of Scabies (2020 IACS criteria).37 38 Cate-
gorisation will be based on the identification of typical 
scabies lesions, typical body distribution of lesions and 
presence of itch and/or positive contact history. Diag-
nosis will therefore use levels B (Clinical Scabies) and C 
(Suspected Scabies) (table 2). Microscopy was not used 
as it is not feasible or practical for programmatic roll- out 
in these remote settings. Confirmation of diagnosis with 
dermatoscopy was not considered feasible as the specialist 
skills required exceeded the training of the local health 
workers.
Impetigo will be recorded if papular, pustular or ulcer-
ative lesions surrounded by erythema, or with crusts, pus 
or bullae are seen.7 This approach is consistent with the 
diagnostic processes in previous scabies community inter-
vention trials. Examinations will be conducted by nurses 
from Western Province. Nurses will receive 1 week of theo-
retical and practical training in the clinical assessment for 
scabies and impetigo, including application of the 2020 
IACS criteria (online supplementary file 2).39 Nurses will 
receive additional training prior to the follow- up surveys 
at 12 and 24 months.
Other severe skin infections such as ulcers, abscesses or 
suspected cases of crusted scabies will also be recorded 
where noted. If these, or other significant medical condi-
tions are noted during the survey, participants will be 
referred off- study to the local health clinic for assessment 
and management.
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In addition to skin examination data, we will also 
collect information on presentations to health facilities 
in the study villages. Government health facilities in 
Solomon Islands routinely record the details of all atten-
dances and admissions in paper- based registers. Cases of 
scabies, local and serious bacterial infections, and other 
skin diseases are recorded. Facilities report aggregated 
data using a standardised form each month. Data is trans-
ferred electronically through the District Health Informa-
tion System (DHIS2) to the MHMS Health Information 
Statistics Unit. We will use the information from DHIS2 to 
assess the number of presentations to health facilities with 
scabies and impetigo. Data collected in the 12 months 
prior to MDA will be compared with data collected in the 
24 months following MDA.
Safety monitoring and reporting
Ivermectin is well tolerated and has a significant dose 
safety margin with no safety concerns at much higher 
doses than clinically required (up to 120 mg in adults, 
approximately 2000 µg/kg).40 41 Over one billion doses 
have been distributed for control of onchocerciasis and 
LF with few effects reported beyond minor, reversible 
events.42 43 There have been cases of encephalopathy 
following ivermectin administration but these have been 
in the context of loiasis, a disease which has not been 
detected in Solomon Islands.44 Ivermectin is on the WHO 
Model Essential Medicines List and the Solomon Islands 
Essential Medicines List for the treatment of scabies.31 45 
Although topical benzyl benzoate is the standard treat-
ment of scabies in the Solomon Islands, topical 5% perme-
thrin will be used in the study due to its increased efficacy 
and lower rate of local side effects.46 Permethrin is well 
tolerated with very few side effects, including in infants.47 48 
Nonetheless, we will record all reported adverse events 
related to treatment using passive monitoring.
Participants will be advised to report any adverse events 
to clinic nurses or directly to the study team if the adverse 
event occurs immediately post MDA. The clinic nurses 
will relay information to the study coordinator who will 
document the adverse event and send a report to the 
Principal Investigator who will, in turn, collate adverse 
events for reporting to the Data Safety Monitoring Board 
(DSMB). Any serious adverse events or suspected serious 
adverse reactions will be reported to the study coordi-
nator by the study team, or clinical staff at the clinics and 
hospitals in the study area. Hospitals will be briefed on 
the study and provided with comprehensive reporting 
forms and the MDA schedule. Hospitals will report any 
admissions or deaths from study villages for 1 month 
following administration of the first dose of ivermectin. 
We will retrospectively review mortality records to ensure 
all deaths from study villages have been captured. We will 
review routinely collected summary data on all stillbirths 
from hospitals in the area for 12 months following MDA.
An independent DSMB will provide oversight to the 
safety and progress of the trial. The DSMB will meet via 
teleconference prior to the study, in the first 3 months 
after MDA and at the conclusion of the study. Any serious 
adverse events and suspected serious adverse reactions 
will be reported to the DSMB within 7 days.
Sample size
Sample size calculations were based on scabies prevalence 
in Western Province of Solomon Islands and the effect 
size measured in previous studies of ivermectin- based 
Table 2 Case definitions for scabies using the 2020 IACS Criteria38
Criteria category Used in survey
Confirmed scabies
  At least one of the following:   
A1 Mites, eggs or faeces on light microscopy of skin samples No
A2 Mites, eggs or faeces visualised on an individual using a high- powered imaging device No
A3 Mite visualised on an individual using dermoscopy No
Clinical scabies
  At least one of the following:   
B1 Scabies burrows No
B2 Typical lesions affecting male genitalia No
B3 Typical lesions in a typical distribution and two history features* Yes
Suspected scabies
  At least one of the following:   
C1 Typical lesions in a typical distribution and one history feature* Yes
C2 Atypical lesions or atypical distribution and two history features* Yes
Diagnosis can be made at one of the three levels (A, B or C). A diagnosis of clinical or suspected scabies should only be made if other 
differential diagnoses are considered less likely than scabies.
*History features include (i) itch and (ii) positive contact history.
IACS, International Alliance for the Control of Scabies.
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MDA for scabies.6 17 21 A standard Monte Carlo simulation 
method with 1000 repetitions was used to estimate the 
required sample size and number of villages to achieve 
statistical power of 80%.49 We assumed that scabies preva-
lence across villages would range from 10% to 30% (mean 
20%, SD 5%) at baseline.6 The effect size measured in 
previous studies with two doses of ivermectin MDA was 
used to assume the prevalence of scabies 12 months after 
MDA will be between 3% and 9% (mean 6%, SD 2%) in 
the one- dose group and between 1% and 5% (mean 3%, 
SD 1%) in the two- dose group.17 21 We assumed an average 
village size of 250 people, with a range of 200 to 300.50 We 
considered a non- inferiority margin of 5% (prevalence of 
scabies at 12 months in the one- dose group minus preva-
lence at 12 months in the two- dose group) to be relevant 
from a public health perspective. Based on these assump-
tions, 20 villages, randomised equally, would be sufficient 
to achieve the required power.
Randomisation
An independent statistician will randomise villages to 
the one- dose or two- dose group in a 1:1 ratio once the 
20 study villages have agreed to participate. There will be 
no stratification within the randomisation process. There 
will be 10 villages in each group (figure 3).
Analysis plan
We will account for clustering when calculating all study 
outcomes by calculating outcomes at the cluster level, 
and analysing data at the cluster level and not the indi-
vidual level.51 The range of cluster- level outcomes will be 
reported by group.
Primary outcome
The prevalence of scabies in each village will be calcu-
lated at baseline (0 months) and at 12 months. The 
prevalence will be calculated by dividing the number of 
participants with scabies by the denominator (the total 
number of participants examined for scabies) in each 
cluster. The denominator will vary at each time point as 
we will include all participants who consented for skin 
examination, regardless of their involvement at other 
time points.
The difference in scabies prevalence between baseline 
and 12 months will be calculated for each village. The 
means of these differences will be calculated in the two 
treatment groups and compared by calculating the differ-
ence between the means. If the upper limit of the two- 
sided 95% CI of the mean difference between the two 
study groups is less than or equal to 5% (the clinically 
relevant non- inferiority margin) the one- dose regimen 
will be considered non- inferior.
Secondary outcomes
The analysis for the prevalence of scabies at 24 months 
and impetigo at 12 and 24 months will be done in the 
same way as for the primary endpoint.
The change in the number of presentations to health 
facilities for scabies and impetigo will be analysed in 
three ways. First, the total number of presentations in 
the 12 months before MDA will be compared with the 
number of presentations in months 1 to 12 and 13 to 24 
after MDA. Second, we will calculate the proportion of 
clinic presentations for scabies and impetigo by dividing 
the number of presentations for scabies and impetigo by 
the total number of clinic presentations for any condi-
tion. We will calculate this proportion for the 12 months 
before MDA, 1 to 12, and 13 to 24 months after MDA. 
Calculating the proportion will account for any changes 
in population size or operational status of health facili-
ties. Third, we will compare the number of clinic presen-
tations for scabies and impetigo in the clinics that service 
the study villages and compare this with clinic presenta-
tion for scabies and impetigo in other clinics in the prov-
ince, this will be adjusted for population size.
Figure 3 Study flow diagram. approx., approximately; MDA, 
mass drug administration
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The number of adverse events in each study group 
will be calculated as a proportion of the total number of 
participants in each study group that received MDA at 
baseline. We will also report the number of deaths in the 
month following MDA in each study group as a propor-
tion of the number of participants in each group.
Data collection and management
Data will be collected using a combination of paper- 
based and electronic forms. Paper forms will be stored in 
locked filing cabinets. Information will be de- identified 
and participant names will only be recorded on consent 
forms. Only authorised study staff will be able to access 
forms. Data will be destroyed after 15 years in compli-
ance with local guidelines. Skin examination data will be 
collected and managed using REDCap electronic data 
capture tools hosted at Murdoch Children’s Research 
Institute.52 53 REDCap is a secure, web- based software 
platform designed to support data capture for research 
studies.
Trial status
Baseline data collection and MDA took place between 
May and July 2019. A total of 5260 participants were 
enrolled. Follow- up village data collection is scheduled to 
take place between May and July 2020 and between May 
and July 2021.
Ethics and dissemination
The RISE trial is investigator- initiated and funded by 
the National Health and Medical Research Council of 
Australia (GNT1127297). The funder was not involved in 
protocol development or the study process, including site 
selection, management, data collection or analysis of the 
results. The trial is a collaboration between the Murdoch 
Children's Research Institute, the Solomon Islands 
MHMS, the Kirby Institute at the University of New South 
Wales, the London School of Hygiene and Tropical Medi-
cine and the Australian National University.
The trial was designed in accordance with CONSORT 
(Consolidated Standards of Reporting Trials) guidelines 
and our reporting of the protocol conforms to the Stan-
dard Protocol Items: Recommendations for Interven-
tional Trials (SPIRIT) 2013 checklist.54–56 This trial has 
been approved by the Solomon Islands Health Research 
and Ethics Review Board (HRE005/18) and Royal Chil-
dren's Hospital Human Research Ethics Committee 
(38 099A) in Melbourne, Australia, and will be conducted 
in accordance with Good Clinical Practice.
De- identified data may be made available for further 
analysis with appropriate approvals. Results of the study 
will be presented locally and made available to health 
policy decision makers and clinical staff. Villages that 
participated in the trial will be presented the results in 
a culturally appropriate way that is easy to understand 
and interpret. Participants will have the opportunity for 
results to be explained to them in their own language 
through a series of village meetings as well as printed 
information leaflets.
Patientand public involvement
Patientsand/or the public were involved in the design, 
or conduct, or reporting, ordissemination plans of this 
research. Refer to the Methods section for furtherdetails.
DISCUSSION
Scabies is a common disease in many tropical and low- 
income settings and has been prioritised for control by 
WHO, but there are still gaps in knowledge to deter-
mine the optimum approach to control in settings where 
scabies is highly endemic.9 The results of this trial will 
have an impact on national, regional and global strategies 
for scabies control.
Island communities in the Pacific have among the 
highest global prevalence of scabies and understanding 
how to implement MDA in these settings has the potential 
for translation into huge public health impact for these 
communities.5 However, the results may not be general-
isable to populations with a much lower prevalence of 
the disease, to settings with higher population density or 
to urban settings. The non- inferiority margin of 5% was 
determined using available evidence but may not repre-
sent the appropriate level of public health significance 
in all circumstances. A greater or lesser margin may be 
considered non- inferior in other settings, depending on 
factors, including baseline disease prevalence, number 
of rounds planned, costs of implementing each regimen 
and available resources. This trial is designed to assess a 
single round of MDA, there is scope for further research 
to assess the efficacy of repeated annual rounds of MDA. 
The cluster- randomised design will allow analysis of the 
impact of MDA at the community level. We will be able 
to assess the impact of the intervention on the whole 
community, even for those who will not receive MDA.
If the RISE trial finds that one- dose ivermectin MDA is 
inferior, then the need for two doses of ivermectin- based 
MDA would need to be taken into account in decision- 
making around control strategies for scabies. It would also 
provide impetus for further research to identify new treat-
ments for scabies that may be able to be implemented 
with one dose. Approaches may include novel treatments 
that are ovicidal or other medications with a longer half- 
life such as moxidectin.57 If one- dose ivermectin- based 
MDA is found to be non- inferior to two- dose, then this 
strategy will be highly attractive for implementation as 
a public health programme. The lower cost, simplified 
logistics and ability to integrate with other programmes 
would make scabies control programmes more feasible in 
low- income settings.
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